NCT06327178
Recruiting
N/A
Response to the Combination of Stereotactic Body Radiation Therapy and Concurrent PD-1 Blockade in Patients With Metastatic Renal Cell Carcinoma: a Retrospective Study
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Nanfang Hospital, Southern Medical University
- Enrollment
- 20
- Locations
- 1
- Primary Endpoint
- Objective Response Rate
- Status
- Recruiting
- Last Updated
- 11 months ago
Overview
Brief Summary
Prior research has indicated that stereotactic body radiotherapy (SBRT) can effectively trigger systemic anti-tumor immune response. The goal of this observational study is to learn about abscopal effects of stereotactic body radiotherapy and concurrent anti-PD-1 antibody treatment in patients of metastatic clear renal cell carcinoma. The primary objective was to assess the objective response rate (ORR) in non-irradiated lesions, and incidence of adverse events (AEs).
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age≥18 years at the time of signing informed consent;
- •Histologically confirmed, advanced renal cell carcinoma of stage IV (AJCC 8);
- •Previously received SBRT and concurrent PD-1 blockade treatment；
- •Evidence of measurable metastatic kidney cancer according to RECIST 1.1 criteria.
Exclusion Criteria
- •Patients who cannot be adequately followed up;
- •Has a known additional malignancy that is progressing or requires active treatment.
Outcomes
Primary Outcomes
Objective Response Rate
Time Frame: Up to 2 years.
Study Sites (1)
Loading locations...
Similar Trials
Terminated
N/A
Stereotactic Radiation Therapy and Sorafenib in the Treatment of Hepatocellular CarcinomaHepatocellular CarcinomaLiver CancerNCT01005875University of Alabama at Birmingham5
Unknown
Phase 2
SBRT Compared With IMRT Concurrently With Chemotherapy in Treating Patients With LS-SCLCSmall Cell Lung CancerNCT02738723Third Military Medical University50
Withdrawn
N/A
Stereotactic Body Radiotherapy for Lung Lesions With Markerless Tracking (MLT) on the VERO® SBRT SystemLung CancerStereotactic Body RadiotherapyLung DiseasesLung Cancer MetastaticLung Cancer Stage IVLung Cancer, Nonsmall CellNCT06722885Universitair Ziekenhuis Brussel
Active, Not Recruiting
Phase 2
SBRT Followed by Neoadjuvant Immunochemotherapy in Resectable Stage II to III Non-small Cell Lung CancerCarcinoma, Non-Small-Cell LungNCT05319574Sun Yat-sen University46
Active, Not Recruiting
N/A
Stereotactic Body Radiotherapy (SBRT) for Medically Inoperable Localised Renal Tumors (SABINA Trial)Kidney NeoplasmRenal CancerInoperable DiseaseSBRTSABRNCT05817604Consorci Sanitari de Terrassa60